4th Apr 2016 06:39
LONDON (Alliance News) - Brain health company IXICO PLC on Monday said it has entered into a consortium with a series of major pharmaceutical companies on treating Parkinson's Disease and has signed a contract with UK-listed Oxford Biomedica PLC.
IXICO has joined seven pharmaceutical companies, including UK-listed AstraZeneca PLC and US groups AbbVie Inc, Eli Lilly & Co and Pfizer Inc, in the Critical Path for Parkinson's Consortium.
Formed in partnership with the Critical Path Institute, the group will work on establishing best practice and more efficient protocols on clinical trial planning for Parkinson's treatments.
In addition, IXICO has won a contract from Oxford Biomedica, the gene and cell therapy research and development business, to support the use of brain scanning technology in trials on an experimental Parkinson's treatment. IXICO will work on the trials for up to five years and will provide PET imaging, image data handling and analysis technology.
No financial details on the Oxford Biomedica contract were disclosed.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica